^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Peritoneal Cancer

    2d
    Gastric-Type Endocervical Adenocarcinoma Mimicking Advanced Ovarian Carcinoma: A Diagnostic Challenge with Carcinomatosis and Obstructive Uropathy. (PubMed, Case Rep Oncol)
    Despite her relatively short symptomatic clinical course, the patient exhibited signs of advanced disease, characterized by peritoneal carcinomatosis, vaginal involvement, and obstructive uropathy from pelvic mass effect. This patient's atypical clinical presentation illustrates that GTEC may mimic ovarian-like tumors, resulting in misclassification and diagnostic delay and further underscoring the challenge that HPV-independent tumors such as GTEC pose to current screening strategies and diagnostic frameworks.
    Journal
    |
    ER (Estrogen receptor)
    4d
    A Single-Arm Prospective Clinical Study of Senaparib as First-Line Maintenance Treatment in HRD-Negative Advanced Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (ChiCTR2600117429)
    P=N/A, N=60, Recruiting, Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital, Sun Yat-sen University Cancer Research Institute); Sun Yat-sen Universit
    New trial
    |
    HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HRD
    |
    Paishuning (senaparib)
    4d
    Study on the Correlation Between Mutation Types of BRCA Gene-Positive Epithelial Ovarian Cancer and Clinical Baseline Characteristics, Pathological Features, and Prognosis (ChiCTR2600116755)
    P=N/A, N=80, Not yet recruiting, Linyi Tumor Hospital; Linyi Tumor Hospital
    New trial
    |
    BRCA2 (Breast cancer 2, early onset) • WT1 (WT1 Transcription Factor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    4d
    Intraoperative controlled hypotension reduces intraoperative blood loss during retroperitoneal tumor resection: A randomized controlled study (ChiCTR2500115296)
    P=N/A, N=202, Not yet recruiting, SUN YAT-SEN University Cancer Center; Sun Yat-sen University Cancer Center
    New trial
    4d
    The value of microRNA-mRNA regulatory network in early diagnosis of postoperative intestinal ischemic injury in patients with retroperitoneal tumor (ChiCTR2600116623)
    P=N/A, N=150, Recruiting, Jinshan Hospital,FudanUniversity; Jinshan Hospital affiliated to Fudan University
    New trial
    4d
    A real-world study on the use of Senaparib for first-line maintenance treatment of newly diagnosed BRCAwt advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer (ChiCTR2600117526)
    P4, N=50, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New P4 trial
    |
    Paishuning (senaparib)
    4d
    Iparomlimab and tuvonralimab (QL1706) with chemotherapy as neoadjuvant therapy for advanced ovarian cancer, fallopian tube, primary peritoneal cancer with high CD8+ tumor infiltrating lymphocytes (TILs) (ChiCTR2500113846)
    P2, N=35, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    CD8 (cluster of differentiation 8)
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    4d
    A single-arm, phase II clinical study of Sacituzumab Tirumotecan combined with Bevacizumab for the treatment of platinum-resistant epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer (ChiCTR2500112955)
    P2, N=30, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan) • Lucentis (ranibizumab)
    5d
    What is worth knowing about peritoneal metastases in colorectal cancer? (PubMed, Front Surg)
    Overall, outcomes are most favorable when patients are managed in specialized centers by multidisciplinary teams offering individualized, biomarker-informed treatment strategies. Ongoing research into molecular predictors and innovative drug delivery methods is critical to further improving prognosis for this complex patient population.
    Review • Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    5d
    Diet, Hepcidin, and Chemotherapy RDI (clinicaltrials.gov)
    P=N/A, N=100, Active, not recruiting, George Washington University | Recruiting --> Active, not recruiting
    Enrollment closed
    6d
    Autocrine activity of engineered IL-33 mRNA enhances adoptive T-cell therapy for peritoneal carcinomatosis and synergizes with IL-12 mRNA. (PubMed, Theranostics)
    The IL-33 mutein improves cytokine stability and antitumor activity, while combination with IL-12 yields synergistic effects. This strategy holds promise for enhancing ACT in peritoneal carcinomatosis.
    Journal
    |
    IFNG (Interferon, gamma) • IL33 (Interleukin 33) • ST2 (Suppression Of Tumorigenicity)
    6d
    Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy (clinicaltrials.gov)
    P2, N=10, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
    Trial completion • HEOR
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    carboplatin